Eli Lilly Shares Rise on Positive Phase 3 Trial Results for Foundayo
Eli Lilly's stock rose by approximately 2.16% following the release of positive Phase 3 trial data for its oral diabetes drug, Foundayo (orforglipron), at a major medical conference.
Tickers: $LLY